Inozyme Accounts Payable from 2010 to 2025

INZY Stock  USD 1.36  0.02  1.45%   
Inozyme Pharma Accounts Payable yearly trend continues to be fairly stable with very little volatility. Accounts Payable is likely to outpace its year average in 2025. Accounts Payable is the amount Inozyme Pharma owes to suppliers or vendors for products or services received but not yet paid for. It represents Inozyme Pharma's short-term liabilities. View All Fundamentals
 
Accounts Payable  
First Reported
2019-12-31
Previous Quarter
3.5 M
Current Value
2.2 M
Quarterly Volatility
840.2 K
 
Covid
Check Inozyme Pharma financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Inozyme Pharma's main balance sheet or income statement drivers, such as Net Interest Income of 4.9 M, Interest Income of 4.9 M or Depreciation And Amortization of 541.8 K, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 1.49. Inozyme financial statements analysis is a perfect complement when working with Inozyme Pharma Valuation or Volatility modules.
  
Check out the analysis of Inozyme Pharma Correlation against competitors.
For more information on how to buy Inozyme Stock please use our How to Invest in Inozyme Pharma guide.

Latest Inozyme Pharma's Accounts Payable Growth Pattern

Below is the plot of the Accounts Payable of Inozyme Pharma over the last few years. An accounting item on the balance sheet that represents Inozyme Pharma obligation to pay off a short-term debt to its creditors. The accounts payable entry is usually reported under current liabilities. If accounts payable of Inozyme Pharma are not paid within the agreed terms, the payables are considered to be in default, which may trigger a penalty or interest payment, or the revocation of additional credit from the supplier. Accounts payable may also be considered a source of cash, since they represent funds being borrowed from suppliers. Given these cash flow considerations, suppliers have a natural inclination to push for shorter payment terms, while creditors want to lengthen the payment terms. It is the amount a company owes to suppliers or vendors for products or services received but not yet paid for. It represents the company's short-term liabilities. Inozyme Pharma's Accounts Payable historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Inozyme Pharma's overall financial position and show how it may be relating to other accounts over time.
Accounts Payable10 Years Trend
Slightly volatile
   Accounts Payable   
       Timeline  

Inozyme Accounts Payable Regression Statistics

Arithmetic Mean1,393,638
Geometric Mean1,270,635
Coefficient Of Variation50.19
Mean Deviation557,469
Median984,000
Standard Deviation699,521
Sample Variance489.3B
Range2.2M
R-Value0.56
Mean Square Error357.3B
R-Squared0.32
Significance0.02
Slope82,908
Total Sum of Squares7.3T

Inozyme Accounts Payable History

2025M
20241.3 M
20231.2 M
20222.5 M
20212.4 M
20203.1 M
2019901 K

About Inozyme Pharma Financial Statements

Inozyme Pharma investors use historical fundamental indicators, such as Inozyme Pharma's Accounts Payable, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Inozyme Pharma. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Accounts Payable1.3 MM

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Inozyme Stock Analysis

When running Inozyme Pharma's price analysis, check to measure Inozyme Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Inozyme Pharma is operating at the current time. Most of Inozyme Pharma's value examination focuses on studying past and present price action to predict the probability of Inozyme Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Inozyme Pharma's price. Additionally, you may evaluate how the addition of Inozyme Pharma to your portfolios can decrease your overall portfolio volatility.